The effect of Nanobone® in combination with platelet rich fibrin on bone regeneration following enucleation of large mandibular cysts  by Eldibany, R.M. & Shokry, M.M.
Available online at www.sciencedirect.comScienceDirect
Tanta Dental Journal 11 (2014) 100e108
www.elsevier.com/locate/tdjThe effect of Nanobone® in combination with platelet rich fibrin on
bone regeneration following enucleation of large mandibular cysts
R.M. Eldibany*, M.M. Shokry
Faculty of Dentistry, Alexandria University, Egypt
Received 7 March 2014; revised 25 June 2014; accepted 26 June 2014
Available online 26 September 2014AbstractObjective: This study was performed to evaluate the healing kinetics of combining Nanobone® and PRF following enucleation of
large mandibular cysts.
Materials and methods: 15 patients with large mandibular odontogenic cysts were treated by enucleation and grafting the bone
defects by a combination of Nanobone® and PRF. Post-operative clinical and radiographic follow-up were performed. The change
in the surface area and bone density of the bone defects was measured using cone beam computerized tomography (CBCT)
immediately post-operatively, and after 6 and 9 months.
Results: Accelerated wound healing was observed in all cases without any signs of post-operative complications. On the 9th
month post-operatively the surface area decreased by 51% and there was an increase of 50.8% in bone density.
Conclusion: Nanobone®/PRF combination accelerated bone healing and improved the quality and quantity of regenerated
bone.
© 2014, Production and Hosting by Elsevier B.V. on behalf of the Faculty of Dentistry, Tanta University.
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Open access under CC BY-NC-ND license.region [1]. Their origin, mechanism of growth, as well
as treatment related problems have been often dis-
cussed. What remains often problematic is the healing
of bone defects following the surgical removal of cysts
[2e5]. This is a complicated process particularly after
the removal of medium and large cysts due to the
significant risk of pathological fracture of the weak-
ened bone, requiring long-term postoperative care [6].
Maxillofacial reconstruction is one of the great
challenges faced in clinical research for the develop-
ment of bioactive surgical additives regulating
inflammation and increasing healing [7]. A variety of
treatment modalities including the use of autogenous
bone grafts and bone substitutes materials, guidedthe Faculty of Dentistry, Tanta University.
1 Artoss GmbH, 18119 Rostock, Germany.
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membranes, and growth factors have been proposed to
promote bone regeneration [8].
The drawbacks associated with autogenous bone
grafts have led to the production of a large number of
alternative bone substitute materials. Their biological
behavior depends upon their chemical composition
and physicochemical structure. A group of these syn-
thetic biomaterials are termed osteoinductive bio-
materials. These bone graft substitutes are able to
induce the in vivo environment to form bone [9]. This
also refers to their ability to stimulate and support the
proliferation and differentiation of mesenchymal pro-
genitor cells of the host tissue when implanted in
ectopic sites, together with the induction of bone for-
mation [10e12].
One of these osteoinductive biomaterials is the
NanoBone®, which is a recently developed granular
material consisting of nanocrystalline hydroxyapatite
(ncHA) embedded in a silica gel matrix, which offers
several of the advantages of nanostructural bio-
materials [8,13e16]. The ncHA has an extremely large
internal surface and a material porosity of about 60%.
Animal experiments using this ncHA in the mini pig
critical size defect model showed a significantly higher
rate of bone formation compared to other HA and
tricalcium phosphate (TCP) materials or gelatin
sponges and a nearly complete resorption 8 months
after implantation [17,18].
On the other hand, platelet growth factors are a
well-known source of healing cytokines, usable for
clinical applications. Numerous techniques of autolo-
gous platelet concentrates have been developed and
applied in oral and maxillofacial surgery. The platelet
rich fibrin (PRF) was first developed in France by
Choukroun et al., in 2001. This second generation
platelet concentrate eliminates the risk associated with
the use of bovine thrombin used in the preparation of
platelet rich plasma (PRP) [19,20].
The biochemical analysis of the PRF composition
indicates that this biomaterial consists of an intimate
assembly of cytokines, glycanic chains, structural
glycoproteins enmeshed within a slowly polymerized
fibrin network. These biochemical components have
well known synergetic effects on the healing process.
PRF is not only a platelet concentrate but also an im-
mune node able to stimulate defense mechanisms. It is
likely that the significant inflammatory regulation
noted on surgical sites treated with PRF is the outcome
of retro control effects from cytokines trapped in the
fibrin network and released during the remodeling of
this initial matrix [21e23].In the present study an innovative idea of combining
PRF with Nanobone® was used. Indeed, several studies
have reported clinical success using both these mate-
rials separately. Therefore, the aim of this study was to
evaluate the healing kinetics of combining the Nano-
bone® with the PRF following enucleation of large
mandibular cysts.
2. Materials and methods
This study was conducted on 15 patients, their ages
ranged between 24 and 49 years, suffering from large
mandibular odontogenic cysts (more than 3 cm in
either vertical or horizontal dimensions). The diagnosis
was based on clinical and radiographic examinations.
All patients were treated in the Oral and Maxillofacial
Surgery Department, Faculty of Dentistry, Alexandria
University. This study was approved by the institu-
tional review board, and an informed consent was
obtained from all patients before their inclusion in the
study.
2.1. Nanobone® bone graft
The new ceramic NanoBone®1 used in this study,
consists of hydroxyapatite crystallites with an average
size of 60 nm in each crystallographic direction that
are embedded in a matrix of silica gel. It is produced
by a solegel-technique at temperatures below 700 C,
avoiding sintering of the nanocrystalline hydroxyapa-
tite. In the transition process from sol to gel, a loose
connection of hydroxyapatite crystals with the silicon
dioxide molecules takes place. This connection is
responsible for a nanoporous structured bone substi-
tute. The biomaterial is characterized by numerous
open bonds, which are responsible for an internal
surface of up to 84 m2/g in size. The pore size distri-
bution within the silica gel ranges from 10 to 20 nm in
diameter. Macroscopically, the cone shaped NanoBone
granules possess an average length of 2 mm and an
average diameter of 0.6 mm with a porosity of 60%e
80%.
2.2. Pre-operative phase
A full medical history was conducted for all pa-
tients, as well as the presence or absence of a history of
trauma related to the affected site. Any missing or
decayed tooth was recorded. Sensitivity tests were
performed for teeth involved in the lesion using an
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savable non-vital teeth was performed pre-operatively.
An orthopantomogram was performed to confirm
the diagnosis (Fig. 1), followed by aspiration of the
cystic fluid, although it was difficult to perform in
areas where the buccal cortical plate was thick.
A cone beam computerized tomography scan
(CBCT) was also performed pre-operatively to mea-
sure the exact size and extension of the lesion and to
detect the approximation of the lesion to the inferior
alveolar canal and the mental nerve (Fig. 2).
2.3. Operative phase
All patients were treated under general anesthesia.
The surgical procedure included reflection of a full
thickness mucoperiosteal flap through a sulcular inci-
sion and relaxing vertical incisions, followed by care-
ful removal of bone covering the lesion using rotary
and hand instruments (Figs. 3 and 4). Careful enucle-
ation of the cyst with the capsule and extraction of
impacted or non-savable teeth were performed at the
same time (Fig. 5). This was followed by proper
debridement of the defect site and irrigation with
sterile saline solution (Fig. 6). The cystic lesions were
sent for histopathological examination.
2.4. Protocol for PRF preparation
Twenty ml of blood were collected without antico-
agulant from the brachial vein. The blood was trans-
ferred and equally divided in two 10 ml sterile glass
tube, and was immediately centrifuged using a table
centrifuge at 3000 rpm for 10 min. The absence of
anticoagulant implies the activation of most platelets in
contact with the glass tube walls in a few minutes and
the release of the coagulation cascades. Fibrinogen is
initially concentrated in the high part of the tube,Fig. 1. Pre-operative orthopantomogram showing dentigerous cyst
related to the right impacted mandibular third molar.before the circulating thrombin transforms it into
fibrin. A fibrin clot is then obtained in the middle of the
tube, just between the red corpuscles at the bottom and
the acellular plasma at the top. The success of this
technique depends entirely on the speed of blood
collection and transfer to the centrifuge. Quick
handling is the only way to obtain a clinically usable
PRF clot. After centrifugation, each PRF clot was
separated from the red blood cell base (Fig. 7a and b).
The NanoBone® granules were mixed with the PRF
and the mixture was placed into the defect site (Fig. 8).
The mucoperiosteal flap was repositioned and stabi-
lized using 3-0 black silk suture. All lesions were sent
for histopathological examination to confirm the
diagnosis (Fig. 9).
2.5. Post-operative and follow-up phase
Antibiotics were prescribed to all patients in the
form of 1 gm of Amoxicillin and Clavulanate potas-
sium2 twice a day for five days post-operatively and
non-steroidal anti-inflammatory drug in the form of
Ibuprofen3 400 mg three times daily after meals for
four days and 0.2% chlorhexidine gluconate solution as
a mouth rinse for a period of five days.
Patients were followed-up weekly for the first
month, then monthly for 9 months to assess potential
post-operative complications and to evaluate pain and
tissue healing. Sutures were removed 10 days post-
operatively.
Cone beam computed tomography was performed
immediately post-operatively and on the 6th and 9th
month post-operatively for the assessment of healing of
the bony defects regarding surface area and bone
density using the Galileos software.
3. Results
The present study involved 15 patients suffering
from large mandibular cysts; 8 female patients (53.3%)
and 7 male patients (46.7%). Their age ranged between
24 and 49 years with a mean/SD of 35.13 ± 7.97 years.
Ten patients had cysts within the anterior region of the
mandible (66.7%), while five patients had cysts in the
posterior region of the mandible (33.3%). The results
of the histopathological diagnosis confirmed that 9
patients had inflammatory radicular cysts (60%), while
6 patients had dentigerous cysts related to an impacted
mandibular third molar (40%) (Tables 1 and 2).2 Augmentin™, GlaxoSmithKline, Egypt.
3 Brufen®, Abbott, Egypt.
Fig. 2. CBCT of the dentigerous mandibular cyst showing the exact dimensions of the lesion and the location of the inferior alveolar nerve in
relation to the cyst.
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Healing was uneventful in all cases and normal
color of the overlying mucosa was detected throughout
the follow-up period. Furthermore, the patients did not
complain of any unusual or severe pain. There were no
signs of infection, abnormal reaction, wound dehis-
cence or extrusion of the material in any of the pa-
tients. Only one patient suffered from post-operativeFig. 3. Pre-operative clinical picture.parasthesia that gradually disappeared during the first
month, due to the encroachment of the cyst on the
inferior alveolar nerve.
3.2. Radiographic follow-up
The surface area and the bone density were calcu-
lated immediately post-operatively and at 6 and 9
months post-operatively (Figs. 10 and 11). The mean
surface area/SD of the lesions immediately post-Fig. 4. Bone removal and exposure of the cyst and the impacted
mandibular third molar.
Fig. 5. Enucleated cyst and impacted mandibular third molar.
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there was 31% size reduction of the surface area with a
value of 336.3 ± 57.6 mm2, and on the 9th month the
surface area was recorded as 238.8 ± 56.5 mm2 with a
51% size reduction. By comparing the results obtained
throughout the follow-up period, the decrease of the
surface area of the defect was statistically significant
(Table 3).
Regarding the bone density, it was calculated using
the Hounsfield Unit through the ROI (Region Of In-
terest) within the software. By selecting a 45  45 mm
square placed every time within the center of the
defect, the bone density was calculated and recorded.
The mean bone density/SD was 153.95 ± 15.04 HU
immediately post-operatively, which increased by
22.2%e188.17 ± 17.33 HU by the 6th month and
continued to increase by 50.8% reachingFig. 6. Bone defect following enucleation of dentigerous cyst and the
impacted mandibular third molar. The inferior alveolar nerve is
exposed.
Fig. 7. a. PRF clot. b. PRF mixed with Nanobone.226.90 ± 33.10 HU by the 9th month. The increase in
bone density was statistically significant throughout
the different follow up periods (Table 4).
4. Discussion
Advancements in mandibular reconstruction have
continued to develop over the past decades. Many re-
searches advocate grafting critical-size bone defects
following enucleation of odontogenic cysts or tumors
to accelerate bone healing and improve the quality and
quantity of the regenerated bone [24,25]. The most
Fig. 8. Grafting the bone defect with the Nanobone/PRF mixture.
Table 1






Min. e max. 24.0e49.0
Mean ± SD. 35.13 ± 7.97
Median 34.0
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bone replacement grafts. These grafts can promote
tissue or bone regeneration through a variety of
mechanisms. Bone grafting materials include auto-
grafts, allograft, xenografts, and alloplasts. Alloplasts
such as osteoconductive hydroxyapatite have beenFig. 9. Repositiong of the mucoperiosteal flap.widely used in periapical surgery to enhance new bone
formation [13].
Among the variety of grafting materials, PRF has
become a focus of current studies due to its potential to
accelerate and improve the healing process [26].
Therefore, in the present study, we evaluated hy-
droxyapatite Nanobone® in combination with PRF in
bone defects following the enucleation of large
mandibular cysts.
The initial diagnosis and treatment planning were
performed using orthopantomogram and CBCT. The
radiographic findings were compared to the clinical
picture and the surgical biopsy report which estab-
lished the confirmatory histopathological diagnosis of
the cystic lesions. The follow-up was performed for the
assessment of the treatment outcome following cyst
enucleation and grafting of the bone defect, using the
gray scale value measurements of the CBCT.
The use of the CBCT for diagnosis in this study was
highly successful in outlining the boundaries of the
mandibular canal and the mental nerve to avoid sur-
gical nerve damage. This is in accordance with Stoet-
zer et al. [27] in 2013, where they concluded that the
CBCT was superior to conventional CT in detecting
cortical bone involvement and delineating the
mandibular canal. They stated that when there is
resorption of the cortex of the mandibular canal and the
cyst lining is in close proximity to the inferior alveolar
nerve, enucleation can damage the nerve and lead to
postoperative parasthesia.
All cases in this study demonstrated accelerated
wound healing without any signs of post-operativeTable 2
Distribution of studied cases according to location of cyst (n ¼ 15).
No. %
Location of cyst
Anterior region 10 66.7
Posterior region 5 33.3
Fig. 10. Surface area & bone density measurement 6 months post-operatively.
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face area of the bone defects on the 6th month and 51%
size reduction on the 9th month post-operatively.
Regarding the bone density, there was an increase of
22.2% on the 6th month, reaching 50.8% by the 9th
month.
The results of this study showed that the Nanobone/
PRF mixture accelerated bone healing and improved
the quality and quantity of the regenerated bone. The
rate of increase of the bone density and decrease in theFig. 11. Surface area & bone density measurement 9 months post-
operatively.surface area of the bone defects is significantly supe-
rior to other studies where the defects were left to heal
spontaneously without bone graft. This could be
demonstrated by the study performed by Pradel et al.
[24] in 2006, where the bone density showed an in-
crease of 48% after 12 months as compared to the
immediate postoperative values following the enucle-
ation of large mandibular cysts without grafting. Also,Table 3








Surface area of the defect
Min. e Max. 420.2e542.6 262.5e462.8 177.6e359.8
Mean ± SD. 487.5 ± 32.0 336.3 ± 57.6 238.8 ± 56.5
Median 490.1 315.5 220.1
% of reduction 31.0 51.0
p1 <0.001* <0.001*
p2 <0.001*
p1: p value for paired t-test for comparing between immediately post-
operative period and each other studied periods.
p2: p value for paired t-test for comparing between the 6th month and
the 9th month.
*: Statistically significant at p  0.05.
Table 4









Bone density within the defect
Min. e Max. 135.6e180.1 165.80e214.80 188.40e298.80
Mean ± SD. 153.95 ± 15.04 188.17 ± 17.33 232.14 ± 33.10
Median 148.70 187.30 226.90
% of increase 22.2 50.8
p1 <0.001* <0.001*
p2 <0.001*
p1: p value for paired t-test for comparing between immediate post-
operative and each other studied periods.
p2: p value for paired t-test for comparing between 6 months and 9
months.
*: Statistically significant at p  0.05.
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computed analysis of postoperative radiographs
showed mean values of reduction in the size of the
residual cavity of 12.34% after 6 months and 43.46%
after 12 months, while the increase in bone density was
37% after 6 months and 48.27% after 12 months.
In two studies performed by G€otz et al. [17] in 2010
and Harms et al. [29] in 2012, they reported a high
osteoconductivity of nanocrystalline HA. They re-
ported that the presence of silicate ions appears to
promote the process of bone formation and remodeling
at the boneeHA interface, as well as induction of
angiogenesis, as adequate blood supply is a prerequi-
site for cellular activity. In contrast to what was
observed with other HA-based bone substitute mate-
rials, the rapid osseointegration of nanocrystalline HA
seemed to prevent its complete degradation. The
Nanobone® particles were completely and firmly
embedded within newly formed bone without a
detectable fibrous interface and with no indication of
an adverse host reaction to the material.
Clinical trials suggest that the combination of bone
grafts along with the growth factors in the PRF may be
suitable to enhance the bone density [30]. Kim et al.
[31] in 2012 used TCP, PRF þ b-tricalcium phosphate
(b-TCP), and recombinant human bone morphogenic
protein2 (rhBMP-2)ecoated TCP in the augmentation
of the maxillary sinus in rabbits. The animals were
killed at 3 days and at 1, 2, 4, 6, and 8 weeks. The
PRF þ b-TCP group showed greater area of bone
formation compared with the TCP and the rhBMP-
2ecoated TCP groups during the evaluation period.
In another study performed by Jayalakshmi et al.
[32] in 2012 where PRF and b-TCP allograft were used
for augmentation of a periapical bone defect, theyconcluded that the addition of PRF to b-TCP acceler-
ates the regenerative capacity of bone, and that when
used in combination they give a predictable clinical
and radiographic evidence of bone formation.
Moreover, B€olu¨kbas‚ı et al., in 2013 [26] conducted
a histologic and histomorphometric study to evaluate
the effect of adding PRF to b-TCP on bone regenera-
tion. They created 5 mm bone defects in both tibias of
6 sheep. The defects were left empty or grafted with b-
TCP, PRF, or PRF/b-TCP. The animals were sacrificed
at 10, 20 and 40 days. Their study revealed that the
PRF/b-TCP group showed the highest ratio of new
bone formation.
Furthermore, Shivashankar et al. [33] in 2013 used
PRF in conjunction with conventional HA crystals for
the augmentation of a bone defect following the
enucleation of a periapical lesion in the maxilla. They
stated that the PRF/HA might have accelerated the
resorption of the graft crystals and would have induced
the rapid rate of bone formation.
5. Conclusion
On the basis of the results obtained from this study,
it can be concluded that the combined use of Nano-
bone® and PRF for bone regeneration following the
enucleation of large mandibular odontogenic cysts
induced accelerated bone healing and improved the
quality and quantity of regenerated bone.
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